Dihydroergocryptine/Caffeine

二氢麦角隐亭/咖啡因

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDihydroergocryptine/Caffeine
Drug Alias Name麦角隐亭咖啡因口服液洛斯宝VASOBRAL
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonistsAdenosine A1 receptor antagonistsAdenosine A2a receptor antagonists
TargetsDopamine receptorsAdenosine A1 receptorAdenosine A2a receptor
Therapy Area/IndicationsDiabetes MellitusDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes DihydroergocryptineCaffeine
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsDiabetes MellitusDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A